Adaptimmune shares drop as Genentech terminates deal once valued at $3 billion

Adaptimmune and Genentech inked the cell therapy research and licensing pact in 2021.

Source: bizjournals.com Health Care:Pharmaceuticals headlines - April 12, 2024 Category: Pharmaceuticals Authors: Ryan Sharrow Source Type: news